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Abstract: 11 
Composite wafers and films comprising HPMC and sodium alginate (SA) were 12 
formulated for nicotine (NIC) replacement therapy via the buccal route. Magnesium 13 
aluminium silicate (MAS) was added in different concentration ratios (0.25, 0.5, 0.75) 14 
to stabilize NIC and its effect on mechanical properties, internal and surface 15 
morphology, physical form, thermal properties, swelling, mucoadhesion, drug content 16 
and release behaviour of the formulations was investigated. MAS changed the physico-17 
mechanical properties of the composite formulations causing a decrease in mechanical 18 
hardness, collapsed wafer pores, increased roughness of film surface, increase in 19 
crystallinity and decreased mucoadhesion of the wafers. However, MAS increased 20 
swelling in both films and wafers as well as interaction between NIC and SA, which 21 
increased drug-loading capacity. Further, MAS resulted in rapid and slow release of 22 
NIC from wafer and films respectively. The results suggest that the ideal formulation 23 
for the stabilization of NIC in the composite formulations was MAS 0.25.  24 
 25 
Keywords: Buccal delivery; Magnesium Aluminium Silicate (MAS); Nicotine; Nicotine 26 
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 28 
1 Introduction  29 
Nicotine has been utilised as an active ingredient in the development of NIC 30 
replacement therapy (NRT) via the oral mucosa (chewing gum, sublingual tablets, 31 
lozenges), nasal mucosa (nasal spray and inhalers) and the skin (transdermal patch). 32 
NIC liquid is volatile, alkaline and colourless with two well-separated pKa values of 33 
3.04 and 7.84, which can form diprotonated, mono-protonated and neutral NIC species 34 
in an acid, neutral or basic solvent respectively (Pongjanyakul & Suksri, 2009). These 35 
species can permeate membranes such as nasal, buccal and sublingual mucosae with 36 
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unionized species showing higher permeation than ionized forms (Nair, Chetty, Ho, & 37 
Chien, 1997).  38 
The oral mucosa of delivery has gained increased interest because of its ability 39 
to avoid gastric acid, enzymes in the small intestine and first pass metabolism in the 40 
liver, common with the conventional oral route (Sattar, Sayed, & Lane, 2014). The 41 
buccal mucosa is highly vascular, less vulnerable to irritation and has a lower amount of 42 
enzyme activities compared to intestinal, rectal, vaginal and nasal mucosae (Boateng & 43 
Okeke, 2014). Though the use of the buccal mucosa for NIC delivery has been 44 
demonstrated in NIC chewing gum, Nicorette®, a large percentage of the drug is 45 
swallowed before achieving complete absorption (Nair et al., 1997; Adrian, Olin, 46 
Dalhoff & Jacobsen, 2006; Benowitz, Jacob, & Savanapridi, 1987).  47 
Alternative buccal delivery systems, which can be utilised in NRT using 48 
mucoadhesive polymers have been under investigation including films (Aguzzi, Cerezo, 49 
Viseras, & Caramella, 2007) and wafers (Aguzzi et al., 2007; Boateng & Areago, 2014) 50 
and demonstrated improved functional properties when different polymers were 51 
combined. Hydroxypropylmethylcellulose (HPMC) and sodium alginate (SA) have 52 
been widely used as mucoadhesive polymers in the development of buccal-adhesive 53 
drug delivery systems (Boateng & Areago, 2014; Manivannan, Balasubramaniam, 54 
Anand, Sandeep, & Rajkumar, 2008; Adhikari, Nayak, Nayak, & Mohanty, 2010; 55 
Pandey, Hingawe, Das, & Patil, 2014; Khan, Boateng, Mitchell, & Trivedi, 2015). 56 
HPMC is a hydrophilic non-ionic semi-synthetic polymer widely used in the 57 
pharmaceutical and food industries while SA is a poly-anionic polysaccharide polymer 58 
made up of alginic acid (a polyuronic acid composed of mannuronic and guluronic acid 59 
residues), extracted from brown seaweed. HPMC-SA composites were reported for the 60 
4 
 
formulation of buccal NIC tablets for smoking cessation (Ìkinci, Şenel, Wilson, & 61 
Şumnu, 2004). 62 
The challenges posed by NIC are its volatility and oxidative degradation of the 63 
free base. To address these challenges, there has been research into the adsorption of 64 
NIC onto several materials such as cellulose powder (Mihranyan, Andersson, & Ek, 65 
2004), cation exchange resins (Rakić et al., 2010) and inorganic clays such as 66 
magnesium aluminium silicate (MAS) (Pongjanyakul & Suksri, 2009). In particular, 67 
polymer-clay composites having improved mechanical properties, thermal behaviour 68 
and modified drug release have attracted interest in the field of drug delivery (Aguzzi et 69 
al., 2007; Gilman, 1999; Pavlidou & Papaspyrides, 2008).  70 
MAS results from the combination of natural smectites (montmorillonite and 71 
saponite clays) that forms a layered structure (Rowe, Sheskey, & Owen, 2006; 72 
Pongjanyakul & Suksri, 2009), comprising three-lattice layers of octahedral alumina or 73 
magnesia and two tetrahedral silica. Upon hydration, the MAS layered structure 74 
separates, exposing the weakly positively charged edges and negatively charged faces. 75 
This can readily interact with amine drugs such as NIC, as well as demonstrate 76 
electrostatic interaction, which contributes to slow drug release in formulations 77 
(Pongjanyakul & Suksri, 2009; Rowe et al., 2006). MAS incorporated into NIC loaded 78 
single polymer (SA) based films demonstrated interaction of MAS with anionic SA 79 
polymer as well as increase in NIC retention within the films (Pongjanyakul & Suksri, 80 
2010). 81 
In this study, composite SA based films and wafers containing different 82 
concentrations of MAS, loaded with NIC were characterised and compared for the first 83 
time. The hypothesis is that the presence of SA and MAS within a composite 84 
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formulation will stabilize NIC and result in high drug loading suitable for NRT via the 85 
buccal mucosa.  86 
 87 
2 Materials and methods 88 
2.1 Materials 89 
Hydroxypropylmethylcellulose - HPMC (Methocel K100 premium LV) and 90 
Magnesium aluminium silicate (MAS) were gifts from Colorcon Limited (Dartford, 91 
UK) and R.T. Vanderbilt Company Inc (Norwalk, CT, USA) respectively. Sodium 92 
hydroxide, potassium dihydrogen phosphate, gelatine were purchased from Fluka 93 
Analytical (Buchs, Switzerland). Nicotine (liquid form), sodium alginate –SA 94 
(molecular weight 120,000 – 190,000 g/mol, mannuronate/guluronate ratio 1.56), and 95 
mucin from porcine stomach were all obtained from Sigma Aldrich (Dorset, UK); 96 
sodium acetate, trimethylamine and glycerol were purchased from Fisher Scientific 97 
(Loughborough, UK). 98 
2.2 Preparation of composite films 99 
NIC loaded MAS films were prepared in different ratios with a total polymer (HPMC-100 
SA) concentration of 2% w/v. The concentrations of polymers, MAS, plasticizer and 101 
drug used in each polymer solution have been summarised in Table 1a. The polymeric 102 
solutions for film formulation were prepared by dissolving glycerol (GLY) in 80ml of 103 
distilled water while stirring at of 25°C before gradually adding HPMC and SA powder 104 
one after the other and stirred between 500-700rpm for 2 hours. MAS on the other hand 105 
was dissolved in 20ml of hot distilled water (50°C) for 30 mins, and mixed with the 106 
dispersed polymeric solution. The resulting final solutions were left overnight (16-20 107 
hrs) to eliminate air bubbles, NIC added to the MAS composite mixture and stirred at 108 
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low rpm (100-200rpm) for 30 mins. 30 g of the NIC loaded MAS solutions were poured 109 
into a Petri dish (90mm diameter) and dried in an oven at 30°C for 18-20 hrs.  110 
Table 1: (a) Composition of selected polymer, plasticizer, MAS and NIC used in 111 
composite gel for film formulation and (b) Composition of selected polymers, MAS and 112 
NIC used in composite gels for formulating wafers. 113 
(a) Films 114 
Sample name HPMC  
(% w/v) 
SA  
(% w/v) 
GLY  
(% w/v) 
MAS 
 (% w/v) 
NIC  
(g) 
MAS 0.00 1.25 0.75 2.00 0.00 0.20 
MAS 0.25 1.25 0.75 2.00 0.25 0.20 
MAS 0.50 1.25 0.75 2.00 0.50 0.20 
MAS 0.75 1.25 0.75 2.00 0.75 0.20 
 (b) Wafers 115 
2.3 Preparation of composite wafers 116 
NIC loaded HPMC-SA-MAS solutions were prepared in a similar manner to films but 117 
without using GLY. The solutions (1g) were poured into each well of a 24 well plate 118 
Sample name HPMC  
(% w/v) 
SA  
(% w/v) 
MAS 
 (% w/v) 
NIC  
(g) 
MAS 0.00 1.25 0.75 0.00 0.20 
MAS 0.25 1.25 0.75 0.25 0.20 
MAS 0.50 1.25 0.75 0.50 0.20 
MAS 0.75 1.25 0.75 0.75 0.20 
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(diameter 15.5mm). The concentrations of polymers, MAS and drug present in each 119 
solution are summarised in Table 1b. The freeze-dried wafers were prepared using an 120 
automated lyophilisation cycle, Virtis Advantage XL 70 freeze-dryer (Biopharma 121 
process systems, Winchester, UK). The well plates containing the gels were loaded onto 122 
the shelves of the freeze-dryer and programmed for freezing, primary drying and 123 
secondary drying steps. The freezing step involved cooling the sample from room 124 
temperature to 5°C (40 mins), 5°C to -10°C (40 mins), and then from -10°C to -55°C 125 
(120 mins). An annealing step was incorporated into the freezing cycle by increasing 126 
the temperature from -55°C to -35°C (2 hrs) and then cooling back down to -55°C (3 127 
hrs). Additional freezing was performed at -55°C (1 hr) with a condenser temperature of 128 
-55°C under pressure (200mTorr). The primary drying occurred under high pressure of 129 
50mTorr. The temperature was raised from -55°C to -20°C (8 hrs) and further increased 130 
from -20°C to -15°C ° (10 hrs). Secondary drying occurred at 50mTorr, from -15°C to 131 
25°C (12.5 hrs).  132 
2.4 Polymer solution properties 133 
The polymeric solutions were analysed for surface stickiness, stringiness and gel 134 
strength using a texture analyser (HD plus, Stable Micro System, Surrey, UK) equipped 135 
with a 5 kg load cell. A 25mm probe was lowered onto the solution at a speed of 136 
1mm/sec, held for 2 sec, and then withdrawn at a speed of 8mm/sec. The maximum 137 
force at withdrawal of probe from sample was recorded as surface stickiness while the 138 
distance from the onset and offset of force while moving the probe away from the 139 
sample was recorded as stringiness. The viscous ‘gel’ strength was recorded as the 140 
maximum force as the probe penetrated the polymeric solution to the required depth. 141 
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2.5 Mechanical characterization using texture analysis (TA) 142 
2.5.1 Tensile properties of films 143 
The tensile properties of the films were analysed using a texture analyser (HD plus, 144 
Stable Micro System, Surrey, UK) equipped with a 5 kg load cell. The films (dumb-bell 145 
shaped) were fixed between two tensile grips of the TA instrument and then stretched at 146 
a test speed of 2mm/sec till breaking point. The elongation at break (%), tensile strength 147 
and elastic modulus were determined (n=3) (Morales & McConville, 2011). 148 
2.5.2 Mechanical properties of wafers (hardness) 149 
The resistance to compressive deformation (hardness) of the freeze dried wafers was 150 
determined using a texture analyser (HD plus, Stable Micro System, Surrey, UK) 151 
equipped with a 5 kg load cell. The wafers were compressed to a depth of 2mm using a 152 
2mm cylinder stainless steel probe in compression mode at a speed of 1mm/sec. Wafers 153 
were compressed on 5 different sides (n=3). 154 
2.6 Scanning electron microscopy (SEM)  155 
The surface morphology of films and wafers were analysed using a Hitachi SU8030 156 
(Hitachi High-Technologies, Krefeld, Germany) scanning electron microscope. 157 
Formulations were cut and placed on an Agar Scientific G301 aluminium pin-type 158 
stubs, using an Agar Scientific G3347N double-sided adhesive carbon tape. The films 159 
were carbon coated, while wafers were gold coated using a Sputter Coater (Edwards 160 
188 Sputter Coater S1508). The films and wafers were analysed at 2.0kV and 5.0kV 161 
accelerating voltage respectively. 162 
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2.7 Wafer porosity  163 
Pore analysis was performed in order to evaluate the porosity of wafer structure. The 164 
wafers were initially weighed and then immersed in 5ml of ethanol in a glass vial and 165 
left to stand for 10 mins to allow complete saturation with ethanol. The vials with 166 
ethanol and wafers were degassed to remove air bubbles entrapped in the wafers for 10 167 
mins. The wafers were carefully removed from the solvent, gently wiped to remove 168 
excess solvent, and immediately weighed, to minimise loss of ethanol. 169 
The percentage porosity of wafers was calculated using equation 1 below: 170 
𝑃 =  
𝑉𝑝
𝑉𝑔
 × 100 =
𝑊𝑓−𝑊𝑖
𝜌𝑒𝑉𝑔
 (1) 171 
Where 172 
Vp = pore volume 173 
Vg = wafers geometrical volume 174 
Wf = final wafer weight 175 
Wi = initial wafer weight 176 
ρe = ethanol density (0.789 g/cm3) 177 
2.8 X-ray diffraction (XRD)  178 
The physical (crystalline/amorphous) form of NIC loaded MAS films and wafers was 179 
investigated using a D8 Advantage X-ray diffractometer. Films were cut into small 180 
pieces whilst wafers were compressed, placed on the holder and mounted onto the 181 
sample cell. For pure starting materials, mylar was used to hold the powders before 182 
placing on the sample cell. The samples were analysed in transmission mode at a 183 
diffraction angle ranging from 5° to 50° 2θ, step size 0.04°, and scan speed of 0.4s/step. 184 
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2.9 Attenuated total reflectance Fourier transform infrared spectroscopy 185 
(ATR-FTIR)  186 
ATR-FTIR spectra were obtained from a Perkin Elmer Spectrum instrument equipped 187 
with a diamond universal ATR-unit. Strips of films and wafers and polymer powders 188 
were separately placed on the ATR diamond crystal and force applied using a pressure 189 
clamp to allow adequate contact between the sample and diamond crystal. NIC required 190 
no force application as the liquid could form intimate contact with the diamond crystal. 191 
The resolutions of the samples were recorded at 4 cm-1 within the range of 450-4000 192 
cm-1. Background spectra were subtracted in other to obtain a reliable absorbance of 193 
each sample. 194 
2.10 Swelling  195 
The swelling capacities of films and wafers were determined by immersing each 196 
formulation into 5ml of phosphate buffered saline (pH 6.8; ionic strength, 0.07M) and 197 
change in weight recorded at time intervals of 2 mins up to 30 mins. For every time 198 
interval, the medium was carefully removed to obtain an accurate weight of the sample 199 
and replaced with fresh medium. Three replicates were performed for each sample and 200 
swelling index (%) was calculated using equation 2 (Nair et al., 2013). 201 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑖𝑛𝑑𝑒𝑥 =
𝑊𝑠−𝑊𝑑
𝑊𝑑
× 100 (2) 202 
Where Wd = dry weight of film or wafer. 203 
  Ws = weight of film or wafer after swelling. 204 
2.11 Mucoadhesion  205 
Adhesion test was performed on films and wafers using a TA. HD plus texture analyser 206 
(Stable micro systems, Surry, UK) in tensile mode and fitted with a 5kg load cell. Films 207 
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were cut to match the mathematical area of wafers (a circle with diameter = 15.5mm). 208 
The formulations were attached to an adhesive probe (75mm diameter) of the TA 209 
instrument using a double-sided adhesive tape. Gelatine solution (6.67% (w/v)) 210 
prepared at 70°C (stirred at 500-700rpm) was poured into a Petri dish (86mm diameter) 211 
and immediately placed in a fridge overnight (16-20 hrs) to set into solid gel, and 0.5 ml 212 
of mucin solution (2% (w/v)) prepared in phosphate buffered saline (pH 6.8; ionic 213 
strength, 0.07M) at room temperature was evenly spread on the gelatine gel to represent 214 
the buccal mucosa. The probe with formulation attached was lowered to make contact 215 
with the model buccal mucosa surface for 60 sec, at an applied force of 1.00N, and then 216 
detached. Mucoadhesive strength was determined by the peak adhesive force (PAF) 217 
required to detach the sample from the gelatine surface, total work of adhesion (TWA) 218 
was determined by the area under the force-distance curve, while cohesiveness 219 
represents the distance the samples travelled till they detached from the model buccal 220 
surface. Texture Exponent 32® software was used in collecting and processing the data 221 
from the TA analyser. 222 
2.12 High performance liquid chromatography (HPLC)  223 
NIC was analysed by HPLC using an Agilent 1200 HPLC instrument (Agilent 224 
Technologies, Cheshire, UK) with an auto sampler. The column used was a C-18 225 
reverse-phase column, 4.6 x 250mm (Phenomenex, Cheshire, UK). Trimethylamine, 226 
methanol and sodium acetate (88:12:0.5 v/v) were used as mobile phase and pH 227 
adjusted to 4.2 using glacial acetic acid. Mobile phase flow rate was 1ml/min and 228 
wavelength detection was set at 259nm (Pongjanyakul & Suksri, 2010). The retention 229 
time of NIC was detected at approximately 4.5 min. Calibration curve was plotted using 230 
standards with NIC concentration ranging from 40µg/ml to 400µg/ml (R2=0.9994). 231 
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2.13 Drug content  232 
The content of NIC in NIC loaded MAS films and wafers was assayed by accurately 233 
weighing and dissolving films and wafers in 10ml of distilled water. The films and 234 
wafers were accurately weighed (20-40mg) and recorded in determining the drug 235 
content. The resulting solution was collected into a syringe, filtered through a 0.45µm 236 
cellulose acetate membrane, transferred into HPLC vials and placed in HPLC sample 237 
chamber and analysed as described above (n=3). 238 
2.14 In vitro drug dissolution 239 
In vitro drug dissolution of NIC loaded films and wafers was performed using a Franz-240 
diffusion cell apparatus. The receptor compartment was filled with 8ml of phosphate 241 
buffer (pH 6.8) with a mesh (1mm mesh size) on the receptor surface. The donor and 242 
receptor compartments were sealed with paraffin to limit evaporation and held together 243 
by a pinch clamp. The system was placed on a water bath at 37°C with magnetic stirring 244 
at approximately 200rpm. Formulations were accurately cut, weighed (20-40 mg) and 245 
placed on the mesh between the donor and receptor compartments. At predetermined 246 
time intervals, 0.5ml aliquots of the dissolution media were withdrawn using a 1ml 247 
syringe, filtered through a 0.45µm cellulose acetate membrane, transferred into HPLC 248 
vials and analysed using HPLC. The aliquot withdrawn was always replaced with fresh 249 
buffer solution at 37°C. The percentage cumulative drug released from both films and 250 
wafers were calculated and plotted against time (n=3). 251 
Experimental release data was fitted to various kinetic models using 252 
representative plots. These plot profiles include: cumulative % drug release vs time 253 
(zero order kinetic model); log cumulative of % drug remaining vs time (first order 254 
kinetic model); cumulative % drug release vs square root of time (Higuchi model); cube 255 
root of drug % remaining in matrix vs time (Hixson-Crowell cube root law); and log 256 
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cumulative % drug release vs log time (Korsmeyer-Peppas model). (Dash, Murthy, 257 
Nath, & Chowdhury, 2010; Singhvi & Singh, 2011). 258 
2.15 Statistical analysis 259 
The results were expressed as mean (± standard deviation) and statistical analysis was 260 
performed using student t-test and / or one-way ANOVA to compare results. The 261 
significant differences of data were determined at a level of p < 0.05. 262 
3 Results 263 
3.1 Polymer solution properties 264 
The pH of the HPMC-SA solutions was neutral but increased to between pH 9-10 upon 265 
addition of NIC.  NIC loaded HPMC-SA-MAS solutions were less viscous and 266 
therefore flowed easily when poured into both the well plates and Petri-dishes for 267 
wafers and films respectively.  268 
Table 2: Surface stickiness, stringiness and gel strength of HPMC-SA-MAS gel 269 
formulations 270 
 
Formulations 
Surface stickiness (g) Stringiness (mm) Gel strength (g) 
MAS 0.00 15.51 ± 9.30 0.80 ± 0.27 804.42 ± 268.81 
MAS 0.25 18.98 ± 1.64 0.88 ± 0.08 981.45 ± 111.59 
MAS 0.50 4.15 ± 0.39 0.53 ± 0.07 184.09 ± 10.30 
MAS 0.75 20.91 ± 0.708 0.85 ± 0.05 541.51 ± 153.24 
 271 
The  HPMC-SA-MAS solutions (Table 2) also demonstrated increase in surface 272 
stickiness, stringiness and ‘gel’ strength with initial increase in MAS concentration 273 
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from MAS 0.00 to MAS 0.25, but a decrease in stickiness, stringiness and gel strength 274 
for MAS 0.50 formulation and a subsequent increase in stickiness, stringiness and ‘gel’ 275 
strength for the MAS 0.75 formulation. Overall, the MAS 0.25 formulation 276 
demonstrated the highest value of stringiness and ‘gel’ strength compared to other 277 
formulations, while MAS 0.75 formulation demonstrated the highest value of surface 278 
stickiness. However, MAS 0.50 formulation demonstrated the lowest value of 279 
stickiness, stringiness and ‘gel’ strength compared to the other MAS loaded 280 
formulations. NIC loaded solutions were transparent with light brown colour but 281 
transparency decreased as MAS concentration increased. 282 
 283 
3.2 Texture analysis (TA) 284 
3.2.1 Tensile properties of films 285 
Figure 1a shows the tensile profiles of NIC loaded SA based composite films at 286 
different MAS concentrations. The tensile strength of NIC loaded SA based composite 287 
films ranged from 4.98 ± 0.55N/mm to 6.58 ± 0.15N/mm. There was a gradual increase 288 
in tensile strength as the concentration of MAS increased. Films with the lowest 289 
concentration of MAS (0.25) showed the lowest tensile strength (4.98 ± 0.55 N/mm) 290 
while those with the maximum MAS concentration (0.75) showed the highest tensile 291 
strength (6.58 ± 0.15N/mm). There was also a significant difference (p<0.05) between 292 
MAS 0.25 and MAS 0.75 tensile strength. A gradual increase in elastic modulus was 293 
also observed as MAS concentration increased with the highest concentration of MAS 294 
(MAS 0.75) exhibiting the highest value (28.04 ± 1.2327N/mm2) of elastic modulus. A 295 
decrease in elongation at break (%) was observed as MAS concentration increased 296 
which was most pronounced at the highest concentration of MAS (MAS 0.75) with a 297 
value of 16 ± 0.58 %. Composite films with no MAS demonstrated the highest 298 
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elongation at break (%) of 53 ± 4.27 followed by MAS 0.50 (30 ± 1.85). In general, the 299 
concentration of MAS had an effect on the mechanical properties of NIC loaded 300 
composite films.  301 
 302 
 303 
 304 
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 306 
(b) 307 
Figure 1 (a) Tensile properties of NIC loaded films (n = 3) and (b) Hardness profiles showing 308 
the resistance of NIC loaded wafers (n = 3) to compressive deformation forces.  309 
3.2.2 Mechanical properties of wafer (hardness) 310 
Figure 1b shows the hardness profiles of NIC loaded SA based composite wafers at 311 
different MAS concentrations. The results showed similar hardness values of 1.20 ± 312 
0.10, 1.19 ± 0.15 and 1.18 ± 0.08N for MAS 0.00, 0.25 and 0.50 wafers respectively, 313 
but decreased (0.93 ± 0.06N) for wafers containing the highest amounts of MAS (0.75). 314 
The results show that increase in the concentration of MAS up to MAS 0.50 did not 315 
affect the resistance of wafer to compression deformation force until the concentration 316 
exceeded MAS 0.50 (i.e. MAS 0.75) as demonstrated in Figure 1b.  317 
 318 
3.3 Scanning electron microscopy (SEM)  319 
The internal structures and surface morphology of wafers and films, are shown in 320 
Figures 2 and 3 respectively. Wafers demonstrated a sponge-like and porous internal 321 
structure while the films showed a continuous polymer sheet. The wafers showed 322 
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collapsed pore walls as MAS concentration increased with a highly collapsed wall 323 
observed at MAS 0.75. The films also demonstrated a rough surface morphology as 324 
MAS concentration increased with MAS 0.75 film showing the most uneven surface 325 
compared to other films. 326 
 327 
Figure 2 SEM images of NIC loaded wafers containing different amounts of MAS: (a) MAS 328 
0.00 (b) MAS 0.25 (c) MAS 0.50 and (d) MAS 0.75. 329 
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 330 
Figure 3 SEM images of NIC loaded films containing different amounts of MAS: (a) MAS 0.00 331 
(b) MAS 0.25 (c) MAS 0.50 and (d) MAS 0.75. 332 
 333 
3.4 Wafers porosity 334 
Figure S1 (supplementary data) shows the porosity (%) of SA based composite wafers 335 
at different MAS concentrations. The results demonstrated a decrease in porosity as 336 
MAS concentration in the formulation increased from MAS 0.00 to 0.50, but showed a 337 
sudden increase at maximum MAS concentration (MAS 0.75). However, this cannot be 338 
conclusive because of the degree of error observed between MAS 0.50 and 0.75. 339 
Generally, the result supports SEM results wafers with a better pore structure and 340 
homogeneity observed for HPMC-SA wafer with no MAS present (i.e. MAS 0.00). 341 
3.5 XRD analysis 342 
Figure S2(a) shows XRD transmission diffractograms of pure SA, HPMC, MAS and 343 
mylar (Okeke and Boateng, 2016). HPMC and SA demonstrated a broad peak at 2θ 344 
between 15° - 24° and 20° - 23° respectively suggesting amorphous structure. Unlike 345 
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HPMC and SA powders, MAS demonstrated a crystalline form with diffraction peaks at 346 
2θ values of 20°, 22°, 23° and 29°, and a broad amorphous peak from 2θ of 34° – 38°. 347 
Figure S2(b) showed one crystalline peak at 2θ 23° in NIC loaded composite wafer 348 
without MAS (MAS 0.00) but showed three crystalline peaks at 20°, 22°, 23° for all 349 
other MAS formulations (i.e. MAS 0.25, 0.50 and 0.75), attributed to the presence of 350 
MAS. NIC loaded wafer also demonstrated a broad peak from 2θ 15-24° and from 2θ 351 
34° – 38°. NIC loaded film without MAS showed a broad peak from 2θ 15-24° while 352 
MAS loaded films (i.e. MAS 0.25, 0.50 and 0.75) showed broad peaks from 15-24° 353 
with two crystalline shoulders at 2θ of 20° and 22°. 354 
 355 
3.6 ATR-FTIR spectroscopy 356 
ATR-FTIR spectra of SA, HMPC), GLY, NIC, MAS, NIC loaded composite wafers and 357 
films are shown in Figure 4.  358 
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 359 
Figure 4 ATR-FTIR spectra of (a) pure polymers, GLY, MAS, and NIC, (b) Drug loaded (DL) 360 
MAS wafers and (c) Drug loaded (DL) MAS films. 361 
The characteristic peaks and band assignments of pure polymers, GLY, MAS, NIC, and 362 
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NIC loaded composite wafers and films are summarised in Tables A1 and A2 363 
respectively (supplementary data). NIC loaded wafers and films demonstrated a shift to 364 
higher wavenumber for O-H, O-C=O (asymmetric) and (symmetric) stretching bands. 365 
The Si-O-Al (octahedral Al), characteristic peak of MAS at 517cm-1 was demonstrated 366 
in MAS loaded wafers, with a shift to higher wavelength at 518cm-1, but showed  a shift 367 
to lower wavenumber at 516cm-1 for the corresponding films. However, films without 368 
MAS demonstrated a characteristic C-H peak of GLY with a shift to lower wavenumber 369 
and C-CH3 characteristic peak of HPMC (1314cm
-1) with a shift to higher wavenumber 370 
(1319cm-1).  371 
3.7 Swelling  372 
Figure 5 shows the swelling profiles of both composite wafers and films 373 
containing different concentrations of MAS. Wafers demonstrated a rapid and higher 374 
swelling profile (Figure 5a) compared to films (Figure 5b). A swelling index between 375 
700 - 1150% was observed in wafers and 150 - 700% in films after 2 mins of contact 376 
with PBS solution. Increase in swelling index with incorporation of MAS was 377 
demonstrated in both wafers and films. Although MAS wafers (i.e. MAS 0.25, 0.50 and 378 
0.75) showed higher swelling index than wafers with no MAS (i.e. MAS 0.00), wafers 379 
with MAS 0.75 concentration showed the lowest swelling index among but was still 380 
significantly higher (p=0.0035) than the wafers with no MAS present. In the same way, 381 
films with MAS 0.75 also showed the lowest swelling among the composite films but 382 
was still significantly higher (p=0.0118) than the films without MAS. 383 
 384 
 385 
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(a) 
 
(b) 
Figure 5 Swelling profiles (i.e. swelling index (%) against time) (n = 3) of (a) wafers and (b) 386 
films. 387 
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3.8 Mucoadhesion studies 388 
Figure S3 shows the adhesive properties [(PAF, TWA and cohesiveness 389 
(stickiness)] of NIC loaded wafers and films. The wafers showed a significant (p < 390 
0.05) decrease in PAF from 1.29 ± 0.22N for MAS 0.00 wafer to 0.23 ± 0.003N for 391 
MAS 0.25 wafer, representing about 82% decrease in adhesive force but remained 392 
constant with further increase in MAS concentration. NIC loaded films on the other 393 
hand, demonstrated an increase in PAF as MAS increased. Films showed an increase 394 
from 1.94±0.13N for MAS 0.00 formulation to 2.44 ± 0.44N for MAS 0.75. In general, 395 
there was a significant difference (p < 0.05) in PAF between NIC loaded wafer and 396 
film, with the films showing higher PAF compared to their corresponding wafers 397 
(Figure S3a). The TWA (Figure S3b) of NIC loaded wafers also demonstrated an initial 398 
decrease from 1.01 ± 0.21Nmm for MAS 0.00 to 0.17 ± 0.025Nmm for MAS 0.25, and 399 
then remained constant as MAS concentration increased which was quite similar to the 400 
pattern observed for PAF. NIC loaded films however showed an increase in TWA with 401 
in the presence of MAS, increasing from 1.74 ± 0.52Nmm for MAS 0.25 to 2.28 ± 0.79 402 
for MAS 0.75. The cohesiveness (stickiness’) profiles of NIC loaded wafers and films 403 
are shown in Figure S3c. The cohesiveness of wafers increased with the introduction of 404 
MAS, with a value of 1.92 ± 0.51mm for MAS 0.00 and 9.96 ± 0.71mm for MAS 0.25. 405 
MAS can therefore significantly influence cohesiveness of NIC loaded wafers. 406 
However, in NIC film there was no influence, as cohesiveness remained relatively 407 
constant as MAS concentration increased.  408 
Overall, although NIC loaded composite wafers demonstrated high cohesiveness 409 
(stickiness), NIC loaded MAS films demonstrated better mucoadhesive properties 410 
considering the PAF and TWA profiles. 411 
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3.9 Drug content (% loading / recovery) 412 
Figure S4 shows the drug content of the composite wafers and films and 413 
calculated as percentage drug remaining in the dosage forms after the formulation 414 
process. NIC content was 79 ± 1% and 28 ± 4% respectively for wafers and films 415 
containing no MAS, which increased to 93% and 92% respectively for wafers and films 416 
loaded with MAS 0.25, after which both showed a decrease in NIC content as MAS 417 
increased further. The increase in MAS from MAS 0.00 to 0.25 had the most significant 418 
effect on the NIC content of SA based composite films, with an increase of 419 
approximately 70% compared to wafers which increased by 15%. Further, the 420 
subsequent decrease in NIC content in composite films as MAS concentration 421 
increased, was more pronounced than the corresponding wafers. In the case of wafers, 422 
three formulations MAS 0.25 wafers, MAS 0.50 wafers and MAS 0.75 wafers 423 
maintained the NIC content above 85% whilst only MAS 0.25 films had values above 424 
80%. Due to the very low drug content for MAS films at MAS 0.00, these films were 425 
not employed during in vitro drug dissolution studies. 426 
3.10 In vitro drug dissolution 427 
Figure 6 shows the drug dissolution profiles of MAS wafers and films. The wafers 428 
demonstrated a rapid drug release with about 80-100% of NIC released within 60 mins 429 
while films showed a much more sustained release profile with drug gradually released 430 
from the polymeric matrix. The different wafer formulations showed similar drug 431 
release profiles with no significant difference (p > 0.05) observed as MAS 432 
concentration increased. However, films demonstrated a significant difference (p < 433 
0.05) in percentage cumulative drug release as MAS increased. Films containing MAS 434 
0.25 showed the slowest release rate with a maximum cumulative drug release of 15.1 ± 435 
6.3% at 120 mins followed by MAS 0.50 film (26.1 ± 0.1%) and increased slightly at 436 
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MAS 0.75 film with a cumulative drug release of 35.6 ± 2.7%. 437 
 438 
(a) 439 
 440 
(b) 441 
Figure 6 In vitro drug release profiles (n = 3) of NIC loaded (a) wafers and (b) films. containing 442 
different MAS concentrations.  443 
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3.11 Drug release kinetics 444 
The release parameters of NIC loaded SA based wafers and films have been 445 
summarised in Tables A3 and A4 respectively (supplementary data). Based on the R2 446 
values, drug release from wafers fit the Korsmeyer-Peppas best compared to other 447 
models. However, the release data for films fit the Korsmeyer-Peppas equation for 448 
MAS 0.75 films (R2 = 0.8986) and MAS 0.25 films (R2 = 0.9707) whilst Hixson-449 
Cromwell equation fit the release data for MAS 0.50 films (R2 = 0.9947). The n values 450 
of Korsmeyer-Peppas equation in wafers ranged from 0.3306 - 0.4839 and decreased 451 
with increase in MAS in wafers and less than 0.45 except for MAS 0.00 wafers 452 
(0.4839). Similar to wafers, films demonstrated an n value of less than 0.45, which 453 
ranged from 0.1744 - 0.2363. 454 
 455 
4 Discussion 456 
The introduction of MAS into wafers and film and the presence of SA was to 457 
overcome the challenges posed by NIC as regards to volatility and poor stability. The 458 
increase in surface stickiness, stringiness and gel strength with increase in MAS 459 
concentration was the result of decrease in free volume between the HPMC and SA 460 
polymers as the concentration of MAS increased.  461 
The mechanical hardness of wafers is related to their handling and friability and 462 
therefore consistency of wafer structure can be demonstrated using hardness data as this 463 
shows their resistance to compression deformation forces (Boateng & Areago, 2014). 464 
The consistency in the hardness for wafers containing MAS 0.00 to 0.50 was attributed 465 
to their constant porosities. The decrease in hardness of wafers at higher MAS 466 
concentration (MAS 0.75) is due to the increased porosity and low free volume between 467 
the polymers due to higher MAS solid particles leading to weaker sponge walls. The 468 
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internal microstructure (SEM) also demonstrated weak sponge walls in wafers 469 
containing the highest MAS concentration (MAS 0.75). It’s been reported that an 470 
increase in porosity can reduce hardness as a result of reduced interaction between 471 
polymer chains within the network (Boateng et al., 2010).  472 
The tensile properties of films are very important as they affect ease of handling 473 
and application. Pongjanyakul and co-workers demonstrated the effect of MAS on 474 
elongation and tensile strength, concluding that addition of solid particles usually 475 
decreases films’ elongation (Pongjanyakul et al 2005). SA based films showed a 476 
decrease in percentage elongation with MAS because MAS reduces the free volume 477 
between SA and HPMC (Table 1) which further resulted in the increase in brittleness 478 
(tensile strength) and stiffness (elastic modulus). This could imply that MAS had an 479 
opposite effect to the known plasticising action of GLY. 480 
The physical form of formulations (amorphous or crystalline) can influence 481 
functional characteristics such as water uptake and mucoadhesion (Prabaharan & Gong, 482 
2008). The crystalline peaks demonstrated in both wafers and films were due to the 483 
crystalline nature of the montmorillonite and saponite clay structures of MAS. 484 
Although, crystallinity generally decreases dissolution rate, incorporation of MAS 485 
increased the swelling index due to the interaction between MAS and SA as 486 
demonstrated in ATR-FTIR results and also previously reported (Pongjanyakul et al., 487 
2005). MAS can interact with SA through the formation of hydrogen bonding between 488 
surface silanol groups of MAS and the carboxyl groups of SA and the extent of this 489 
interaction is responsible for the observed changes in characteristics with increase in 490 
MAS concentration.  491 
Suitable hydration and swelling play a major role in mucoadhesion as well as 492 
drug release patterns (Pawar, Tetteh, & Boateng, 2013). In general, the rapid swelling 493 
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profile of wafers compared to films was the result of the sponge-like pores in wafers 494 
microstructure, enabling faster water ingress and making them hydrate faster than the 495 
films. (Pongjanyakul et al., 2005) suggested that the decrease in water uptake in SA 496 
films loaded with MAS was due to the interaction of SA and MAS, which produced a 497 
denser matrix structure and this could have occurred in the case of the films formulated 498 
in this study.  499 
SA based films showed higher mucoadhesion than the corresponding wafers due 500 
to the presence of GLY. This allowed better contact stage via hydrogen bonding and 501 
van der Waals forces (adsorption theory of mucoadhesion) than wafers which were 502 
based on the diffusion theory (Smart, 2005). The increase in mucoadhesion in films as 503 
MAS concentration increased could be attributed to the exposure of weak positive and 504 
negatively charged forces. Upon contact with physiological fluids, the charged MAS 505 
interacts with mucin macromolecules leading to increased van der Waals forces and 506 
electrostatic interactions (Pongjanyakul & Suksri, 2009, Rowe et al., 2006). The 507 
decrease in mucoadhesion of wafers as MAS concentration increased could be due to 508 
the poor contact stage caused by gaps related to the sponge-like pores present in wafers 509 
(Smart, 2005). In addition, MAS can compete with SA and NIC for binding mucin. 510 
However, the increase in MAS showed no noticeable change in adhesion, as the freely 511 
available MAS after interaction with NIC, interacts with SA, therefore reducing the 512 
availability of the SA cationic group to interact with mucin. 513 
The primary aim of incorporating MAS into HPMC-SA wafers and films was to 514 
stabilise NIC. The volatility of NIC base is one of the main reasons for its instability in 515 
formulations as NIC evaporates at high temperature during the drying process (Nair et 516 
al., 1997). MAS can readily interact with amine based drugs through electrostatic 517 
interactions which can improve NIC stability (Pongjanyakul & Suksri, 2009). However, 518 
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higher percentage NIC content was observed in wafers than in the films due to the lower 519 
temperatures used during freeze-drying, compared oven drying.  The decrease in 520 
percentage NIC content in MAS wafers and films at MAS 0.50 and 0.75 can be 521 
explained by the increase in repulsive forces which build-up as MAS concentration 522 
increased. 523 
The release of drug from polymeric matrices such as wafers and films is 524 
dependent on factors such as hydration and eventual swelling of the polymeric dosage 525 
form (Siepmann & Peppas, 2012). As formulations come in contact with dissolution 526 
medium, they undergo hydration, swelling and erosion (dissolution), which was evident 527 
in the swelling behaviour of the various wafers and films. The rapid release (80 - 100% 528 
in 60 mins) of the wafers corresponded to the high swelling index, due to the sponge-529 
like porous internal structure of wafers (SEM and percentage porosity). Therefore, the 530 
use of SA based wafers can be efficient in achieving rapid release of NIC to the buccal 531 
mucosa to ensure rapid easing of the urge to smoke tobacco. The much slower release 532 
of NIC from the films, which corresponded to low swelling index, can be important in 533 
achieving sustained release of NIC, with an extended effect to reduce the need for 534 
frequent administration. The release exponents of MAS loaded formulations of less than 535 
0.45 was outside the limits of Korsmeyer-Peppas model and also highlights the 536 
limitations of the Korsmeyer-Peppas model in the understanding of drug release 537 
mechanisms (Shoaib, Tazeen, Merchant, & Yousuf, 2006). However, the release 538 
exponent of 0.48 for wafers without MAS (MAS 0.00 wafers) shows that drug release 539 
from these wafers followed a Fickian diffusion transport mechanism (Nair et al., 2013).  540 
5 Conclusions 541 
Composite SA based films and wafers, incorporating MAS have been successfully 542 
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formulated as potential buccal delivery systems for NRT. The two formulations 543 
demonstrated different behaviours in their functional physical characteristics. The 544 
wafers showed a porous internal morphology which contribute to higher swelling index 545 
than continuous sheet of films. MAS improved the physical stability of NIC with an 546 
increase in drug loading capacity via molecular interaction between the inorganic clay 547 
and the alkaline drug. The release of drug from the wafers was rapid while release from 548 
the corresponding films was sustained. The MAS stabilized formulations have great 549 
potential as buccal delivery systems for NRT. 550 
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